Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$167.27 USD

167.27
549,714

+2.61 (1.58%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $167.26 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PODD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

1 item in cart

View Cart/Checkout

Insulet Corporation [PODD]

Reports for Purchase

Showing records 241 - 260 ( 340 total )

Company: Insulet Corporation

Industry: Medical - Products

Record: 241

11/06/2014

Company Report

Pages: 9

Q3 results inline, EPS breakeven ex-items, maintain HOLD

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 242

11/06/2014

Company Report

Pages: 7

Some Surprises, But We Stay the Course; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 243

11/05/2014

Company Report

Pages: 8

Insulin Pump Project: Historical survey of ~4,800 pump users (2007 - present)

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 244

10/30/2014

Daily Note

Pages: 5

International End-User OmniPod Sales Grew 60+% Over the Past 6 Months; Maintain OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 245

10/28/2014

Daily Note

Pages: 5

Amgen Showcases OmniPod for Delivery of Neulasta; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 246

10/27/2014

Daily Note

Pages: 53

Initiating Coverage on Insulin Pump Companies

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 247

09/18/2014

Company Report

Pages: 7

CEO transition, revenue guidance reiterated, maintain HOLD

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 248

08/08/2014

Company Report

Pages: 9

OmniPod continues 35% year-over-year growth, guidance trimmed, maintain HOLD

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 249

08/08/2014

Company Report

Pages: 3

A Good, but Complicated Quarter

Provider: The Benchmark Company

Analyst: WALD J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 250

08/05/2014

Company Report

Pages: 7

Insulin Pump Project: Historical survey of 4,500+ pump users (2007 - present)

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 251

05/08/2014

Company Report

Pages: 3

Solid First Quarter, Strength To Continue and Drive Profitability by Year End

Provider: The Benchmark Company

Analyst: WALD J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 252

05/08/2014

Company Report

Pages: 9

Inline Q1 on revs, loss per share above expectations, raise to HOLD from SELL

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 253

05/07/2014

Company Report

Pages: 8

Insulin Pump Project: Historical survey of 4,000+ pump users (2007 - present)

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 254

02/28/2014

Company Report

Pages: 11

Strong Quarter, Guiding 30% OmniPod Growth in 2014, Partnerships Provide Additional Upside

Provider: The Benchmark Company

Analyst: WALD J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 255

02/28/2014

Daily Note

Pages: 11

Morning Call

Provider: The Benchmark Company

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 256

02/28/2014

Daily Note

Pages: 8

Inline Q4 on revs, loss per share above expectations, maintain SELL, PT to $34.50

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 257

02/21/2014

Company Report

Pages: 11

Insulin Pump Project: Historical survey of 4,000+ pump users (2007 - present)

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 258

01/16/2014

Company Report

Pages: 8

2014 Looks to be a Breakout Year; Execution Key

Provider: The Benchmark Company

Analyst: WALD J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 259

01/16/2014

Daily Note

Pages: 8

Morning Call

Provider: The Benchmark Company

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 260

12/10/2013

Company Report

Pages: 8

Putting The Puzzle from Today''s News Together

Provider: The Benchmark Company

Analyst: WALD J

Price: 25.00

Research Provided by a Third Party